Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15995384 | 0.82 | BTK (0.50) | BTK | |
| SCHEMBL16320628 | 0.81 | BTK (0.56) | BTK | |
| SCHEMBL15994195 | 0.81 | JAK2 (0.49) | BTK | |
| SCHEMBL143095 | 0.80 | MEN1 (0.49) | BTKMEN1IKBKBUSP2ALDH1A1 | |
| SCHEMBL16320352 | 0.80 | BTK (0.58) | BTK | |
| SCHEMBL140996 | 0.79 | MEN1 (0.48) | BTKMEN1IKBKBUSP2ALDH1A1 | |
| SCHEMBL146143 | 0.79 | BTK (0.62) | BTK | |
| SCHEMBL16320240 | 0.79 | BTK (0.57) | BTK | |
| SCHEMBL16319812 | 0.79 | BTK (0.54) | BTK | |
| SCHEMBL16319832 | 0.78 | BTK (0.52) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196387-B2 | Carbazole compounds useful as bromodomain inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-05 | — | — | US | disclosed |
| US-10053454-B2 | Carbazole compounds useful as bromodomain inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2961747-B1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2961747-B1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170152248-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152248-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-01 | — | — | US | disclosed |
| US-20160009701-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-14 | — | — | US | disclosed |
| US-20160009701-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-14 | — | — | US | disclosed |
| EP-2961747-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014134267-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014134267-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-04 | — | — | WO | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2370407-B1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2370407-B1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| EP-2370407-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010080474-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080474-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | JAK2, JAK1, JAK3 | BTK 79/4885MEN1 2279/4885IKBKB 225/4885 |
| US-10196387-B2 | Carbazole compounds useful as bromodomain inhibitors | BRD3, BRD4, BRPF3 | BTK 851/4885MEN1 2760/4885IKBKB 1760/4885 |
| US-20160009701-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRD3, BRD4, BRPF3 | BTK 851/4885MEN1 2760/4885IKBKB 1760/4885 |
| US-10053454-B2 | Carbazole compounds useful as bromodomain inhibitors | BRD3, BRD4, BRPF3 | BTK 815/4885MEN1 2778/4885IKBKB 1709/4885 |
| US-20170152248-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRD3, BRD4, BRPF3 | BTK 851/4885MEN1 2760/4885IKBKB 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.